Following a close vote, a U.S. Food and Drug Administration panel has declined to recommend r ivaroxaban ( Xarelto ) to treat acute coronary syndrome.

Patients with certain types of atrial fibrillation, a common heart arrhythmia, are at a high risk of stroke and blood clots if they temporarily stop their blood thinning medication before surgery or permanently because of side effects.

New oral blood thinner rivaroxaban ( Xarelto ) has been shown to be safer for treating a pulmonary embolism as compared to enoxaparin ( Lovenox ) injections, and was found to be just as effective.